American Psychiatric Association 2019 Annual Meeting

The American Psychiatric Association 2019 Annual Meeting features a variety of innovative sessions and tracks focusing on changing the practice and perception of psychiatry. The meeting will take place from May 18-22, 2019, in San Francisco, California. The meeting provides opportunities to learn from renowned experts, discover ground-breaking technology, and understand new therapies. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.
August 15, 2019
Providers should treat patients with schizophrenia by thinking about them as people and understanding the full context of their lives, according to Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University.
August 09, 2019
Providers who treat young people with psychosis must navigate a host of issues unique to this population, including confidentiality and consent rules, the role of the family, and support from schools, according to Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
August 04, 2019
Early intervention is important in many illnesses, including psychosis, so treatment can begin as early as possible for best outcomes, explained Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University. He also discussed a resource for learning more about early intervention.
August 02, 2019
Data presented at the 175th Annual Meeting of the American Psychiatric Association (APA) support the potential of the investigational drug ALKS 3831 to provide the antipsychotic efficacy of olanzapine without the associated weight gain, said Adam Simmons, director of clinical program management, Alkermes. He also discussed the timing of when the data might be filed with the FDA.
July 26, 2019
Adam Simmons, director of clinical program management, Alkermes, explains that an investigational antipsychotic drug, ALKS 3831, provides the efficacy of olanzapine without the associated weight gain can provide benefits in the short and long term to payers and patients. Simmons spoke about data presented at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.
July 25, 2019
Increasing awareness of psychosis can help communities engage with patients on a human level and work together to improve, according to David Kingdon, MD, professor of mental health care delivery, University of Southampton.
July 22, 2019
Isaac Galatzer-Levy, PhD, assistant professor in psychiatry and bioinformatics, NYU School of Medicine, and vice president of clinical and computational neuroscience, AiCure, said that technological solutions like artificial intelligence can help identify and monitor signs of mental illness so patients can be connected with the help they need.
July 17, 2019
Patients with both physical and behavioral health conditions have significantly higher healthcare costs, so integrating both sides of their care can help lower those costs, explained Lori Raney, MD, principal, Health Management Associates.
July 16, 2019
Classifying mental disorders using traditional tools like the Diagnostic and Statistical Manual misses the vast differences in biomarkers that can exist in patients with the same diagnosis, which is why research is looking to biological measures and “biotypes” to provide more information, according to Godfrey Pearlson, MD, professor of psychiatry and neuroscience, Yale School of Medicine.
July 15, 2019
David Kingdon, MD, professor of mental health care delivery, University of Southampton, explained that mental health professionals have been receptive to the use of cognitive behavioral therapy (CBT) in psychosis, but there needs to be greater expansion to increase availability.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.